Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Jun 2:58:e008022025.
doi: 10.1590/0037-8682-0419-2024. eCollection 2025.

Quantitative PCR for parasitemia monitoring and preemptive therapy in patients with Chagas disease and autoimmune rheumatic disorders undergoing biologic treatment: a case series

Noemia Barbosa Carvalho  1 , Vera Lucia Teixeira de Freitas  2   3 , Nadia Emi Aikawa  4 , Lucas Teixeira Vieira  2 , Rita Cristina Bezerra  5 , Adriana Coraccini Tonácio de Proença  1 , Karina Bonfiglioli  4 , Érika Yoshie Shimoda Nakanishi  3 , Hermes Ryoiti Higashino  1 , Maria Aparecida Shikanai-Yasuda  2   3
Affiliations
Case Reports

Quantitative PCR for parasitemia monitoring and preemptive therapy in patients with Chagas disease and autoimmune rheumatic disorders undergoing biologic treatment: a case series

Noemia Barbosa Carvalho et al. Rev Soc Bras Med Trop. .

Abstract

Patients with chronic Chagas disease (CD) and autoimmune rheumatic disorders (ARD) receiving immunosuppressive therapy are at risk for CD reactivation (CDR). This study monitored parasitemia over 9-121 months in six patients with CD and ARD using conventional and quantitative PCR and parasitology. Five patients showed parasitemia; two had elevated levels of parEq/mL (49-458.7). One patient received benznidazole with a marked decrease in parasitemia; in the other, treatment was discontinued after 12 days due to toxicity. No CDR occurred. These findings support the need for qPCR standardization for preemptive therapy and suggest that benznidazole may prevent CDR in patients with high parasitemia.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: The authors declare that they have no conflicts of interest.

References

    1. Jackson Y, Mello DV, Finck A, Chizzolini C, Chappuis F. Chagas disease and systemic autoimmune diseases among Bolivian patients in Switzerland. Mem Inst Osw Cruz. 2018;113(4):e170383 - PMC - PubMed
    1. Salvador F, Sánchez-Montalvá A, Valerio L, Serre N, Roure S, Treviño B, et al. Immunosuppression and Chagas disease; experience from a non-endemic country. Clin Microbiol Infect. 2015;21:854–860. - PubMed
    1. Shikanai-Yasuda MA, Mediano MFF, Novaes CTG, Sousa AS, Sartori AMC, Santana R, et al. Clinical profile and mortality in patients with T. cruzi/HIV co-infection from the multicenter database of the "Network for healthcare and study of Trypanosoma cruzi/HIV co-infection and other immunosuppression conditions". Plos Negl Trop Dis. 2021;15(9) doi: 10.1371/journal.pntd.0009809. - DOI - PMC - PubMed
    1. Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Annals Rheum Dis. 2023;82:3–18. - PubMed
    1. Burgos LG, Ortiz BDM, Canese A, Ojeda A, Melo M. Reactivation of Chagas Disease by Immunosuppressive Therapy in a Patient With Systemic Lupus Erythematosus: Report of an Exceptional Case. Am J Dermatopathol. 2012;34:e84-e89. - PubMed

Publication types

MeSH terms